<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03164057</url>
  </required_header>
  <id_info>
    <org_study_id>AML16</org_study_id>
    <secondary_id>NCI-2017-00928</secondary_id>
    <nct_id>NCT03164057</nct_id>
  </id_info>
  <brief_title>A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia</brief_title>
  <official_title>A Phase II Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Children's Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Children's Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aim of this study is to determine if epigenetic priming with a DNA
      methyltransferase inhibitor (DMTi) prior to chemotherapy blocks is tolerable and carries
      evidence of a clinical efficacy signal as determined by minimal residual disease (MRD),
      event-free survival (EFS), and overall survival (OS). Tolerability for each of the agents, as
      well as total reduction in DNA methylation and outcome assessments will be done to
      simultaneously obtain preliminary biological and clinical data for each DMTi in parallel.

      PRIMARY OBJECTIVES:

        -  Evaluate the tolerability of five days of epigenetic priming with azacitidine and
           decitabine as a single agent DMTi prior to standard AML chemotherapy blocks.

        -  Evaluate the change in genome-wide methylation burden induced by five days of epigenetic
           priming and the association of post-priming genome-wide methylation burden with
           event-free survival among pediatric AML patients.

      SECONDARY OBJECTIVES

        -  Describe minimal residual disease levels following Induction I chemotherapy in patients
           that receive DMTi.

        -  Estimate the event-free survival and overall survival of patients receiving a DMTi prior
           to chemotherapy courses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment will consist of 4 blocks of chemotherapy: Induction I, Induction II,
      Intensification I and Intensification II over approximately 5 months.

      RANDOMIZATION: Patients will be randomized to receive one of two DMTi (azacitidine or
      decitabine) for 5 days prior to Induction I. Intrathecal (ITHMA) treatments will be given
      right before treatment on this study or on Day 1 of Induction I treatment. Leucovorin will be
      given 24-30 hours following ITHMA.

      INDUCTION I CHEMOTHERAPY: Patients receive cytarabine, daunorubicin, and etoposide.

      INDUCTION II CHEMOTHERAPY; Patients receive their assigned DMTi for 5 days followed by
      fludarabine, cytarabine, G-CSF, and idarubicin.

      Patients are then evaluated and assigned to either the low-risk arm or the high-risk arm for
      Intensification therapy.

      INTENSIFICATION I CHEMOTHERAPY - LOW-RISK AML: Patients receive cytarabine and etoposide.
      After administration of 5 days of a DMTi prior to Inductions I and II satisfies a
      tolerability determination criterion, patients will also receive their randomly assigned DMTi
      for five days prior to cytarabine and etoposide.

      INTENSIFICATION II CHEMOTHERAPY - LOW RISK AML: patients receive mitoxantrone and cytarabine.
      After administration of 5 days of a DMTi prior to Inductions I and II satisfies a
      tolerability determination criterion, patients will also receive their randomly assigned DMTi
      for five days prior to cytarabine and etoposide.

      INTENSIFICATION I CHEMOTHERAPY - HIGH-RISK AML: Patients receive mitoxantrone and cytarabine
      followed by stem cell transplant (SCT). After administration of 5 days of a DMTi prior to
      earlier courses satisfies a tolerability criterion, patients will also receive their randomly
      assigned DMTi for five days prior to mitoxantrone and cytarabine.

      INTENSIFICATION II CHEMOTHERAPY - HIGH-RISK AML: Patients who are not referred to transplant
      will receive erwinia asparaginase and cytarabine. After administration of 5 days of a DMTi
      prior to earlier courses satisfies a tolerability criterion, patients will also receive their
      randomly assigned DMTi for five days prior to mitoxantrone and cytarabine.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2017</start_date>
  <completion_date type="Anticipated">June 2027</completion_date>
  <primary_completion_date type="Anticipated">June 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of evaluable patients who tolerate five days of single agent DMTi before a standard chemotherapy combination</measure>
    <time_frame>From enrollment to completion of chemotherapy (up to 8 months after start of therapy)</time_frame>
    <description>Patients will be monitored for grade 4-5 non-hematologic toxic events during these two courses of chemotherapy. Tolerating a course is defined as completing the course without experiencing death or a grade 4 non-hematologic toxicity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in genome-wide methylation burden of leukemia cells from diagnosis to after five days of single agent DMTi</measure>
    <time_frame>From diagnosis to completion of five days of single agent DMTi (up to 2 weeks after start of therapy)</time_frame>
    <description>Leukemic cells will be collected from patients at diagnosis and after five days of single agent DMTi. Each sample of leukemic cells will be profiled with a methylation microarray. For each leukemic sample, genome-wide methylation burden (GWMB) will be computed as the sum of methylation values across all markers. For each patient, the change in GWMB will be computed as the day 5 GWMB minus the diagnostic GWMB.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cox model hazard ratio for association of event-free survival with genome-wide methylation burden</measure>
    <time_frame>From diagnosis to the first of the following events: death, relapse, resistant disease, second malignancy, or last follow-up (up to 3 years after completion of therapy)</time_frame>
    <description>Patients will be monitored for the events of interest from enrollment for at least three years. EFS will be defined as the time elapsed from enrollment to the first of the following events: death, relapse, resistant disease, or second malignancy. EFS times for subjects who have not experienced these events at the time of analysis will be censored at date of last follow-up. A Cox regression model will be used to evaluate the association of EFS with genome-wide methylation burden observed after completion of five days of single agent decitabine or azacitidine as randomly assigned.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of MRD-evaluable subjects with detectable minimal residual disease after receiving five days of a single agent DMTi followed by araC+daunorubicin+etoposide.</measure>
    <time_frame>MRD will be measured after completion of DMTi+araC+daunorubicin+etoposide (up to 6 weeks after the start of therapy)</time_frame>
    <description>Flow cytometry will be used to measure minimal residual disease at diagnosis and after completion of the first course of chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier estimate of event-free survival</measure>
    <time_frame>From diagnosis to the first of the following events: death, relapse, resistant disease, second malignancy, or last follow-up (up to 3 years after completion of therapy)</time_frame>
    <description>Patients will be monitored for the events of interest from enrollment for at least three years. EFS will be defined as the time elapsed from enrollment to the first of the following events: death, relapse, resistant disease, or second malignancy. EFS times for subjects who have not experienced these events at the time of analysis will be censored at date of last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier estimate of overall survival</measure>
    <time_frame>From diagnosis to the first of the following events: death or last follow-up (up to 3 years after completion of therapy)</time_frame>
    <description>Patients will be monitored for death from enrollment for at least three years. Overall survival will be defined as the time elapsed from enrollment to death. OS times for subjects who are living at the time of analysis will be censored at date of last follow-up.</description>
  </secondary_outcome>
  <number_of_arms>24</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>AZA+ADE | FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are randomized to receive 5 days of single agent azacitidine as part of Induction I, and then receive Induction II and low-risk intensifications I &amp; II without azacitidine.
Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G-CSF, mitoxantrone, ITMHA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I &amp; II and low-risk Intensifications I &amp; II.
Interventions: azacitidine, cytarabine, daunorubicin, etoposide,dexrazoxane, fludarabine, idarubicin, G-CSF, mitoxantrone., ITMHA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+AE | AZA+MA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I &amp; II and low-risk Intensifications I &amp; II.
Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G-CSF, mitoxantrone, ITMHA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+AE | MA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I &amp; II and low-risk Intensifications I and then receive low-risk induction II without azacitidine.
Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G-CSF, mitoxantrone, ITMHA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZA+ADE | FLAG-Ida |MA | Asp+AraC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are randomized to receive 5 days of single agent azacitidine as part of Induction I and then receive Induction II and high-risk Intensifications I &amp; II without azacitidine.
Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G-CSF, mitoxantrone, erwinia asparaginase, ITMHA, stem cell transplant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | MA | Asp+AraC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I &amp; II and then receive high-risk Intensifications I &amp; II without azacitidine.
Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G-CSF, mitoxantrone, erwinia asparaginase, ITMHA, stem cell transplant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+MA | Asp+AraC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I &amp; II and high-risk Intensification I. Patients then receive high-risk induction II without azacitidine or stem cell transplant according to donor availability.
Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G-CSF, mitoxantrone, erwinia asparaginase, ITMHA, stem cell transplant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+MA | AZA+Asp+AraC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I &amp; II and high-risk Intensifications I &amp; II. Patients may receive stem cell transplant according to donor availability.
Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G-CSF, mitoxantrone, erwinia asparaginase, ITMHA, stem cell transplant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZA+ADE | FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are randomized to receive 5 days of single agent azacitidine as part of Induction I and then receive Induction II and high-risk Intensifications I &amp; II without azacitidine. Sorafenib is added to the last three courses of chemotherapy. Patients may also receive stem-cell transplant depending on donor availability.
Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G-CSF, sorafenib, mitoxantrone, erwinia asparaginase, ITMHA, stem cell transplant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I &amp; II and then receive high-risk Intensifications I &amp; II without azacitidine. Sorafenib is added to the last three courses of chemotherapy. Patients may also receive stem cell transplant depending on donor availability.
Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G-CSF, sorafenib, mitoxantrone, erwinia asparaginase, ITMHA, stem cell transplant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida+Sor | AZA+MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I &amp; II and high-risk Intensifications I &amp; II. Sorafenib is added to the last three courses of chemotherapy. Patients may also receive stem cell transplant depending on donor availability.
Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G-CSF, sorafenib, mitoxantrone, erwinia asparaginase, ITMHA, stem cell transplant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida+Sor | AZA+MA+Sor | AZA+Asp+AraC+Sor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are randomized to receive 5 days of single agent azacitidine as part of Inductions I &amp; II and high-risk Intensifications I and then receive low-risk induction II without azacitidine. Sorafenib is added to the last three courses of chemotherapy. Patients may also receive transplant depending on donor availability.
Interventions: azacitidine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G-CSF, sorafenib, mitoxantrone, erwinia asparaginase, ITMHA, stem cell transplant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DAC+ADE | FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are randomized to receive 5 days of single agent decitabine as part of Induction I and then receive Induction II and low-risk Intensifications I &amp; II without decitabine.
Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G-CSF, mitoxantrone, ITMHA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I &amp; II and then receive low-risk Intensifications I &amp; II without decitabine.
Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G-CSF, mitoxantrone, ITMHA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+AE | DAC+MA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I &amp; II and low-risk Intensifications I &amp; II.
Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G-CSF, mitoxantrone, ITMHA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+AE | MA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I &amp; II and low-risk Intensifications I and then receive low-risk induction II without decitabine.
Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G-CSF, mitoxantrone, ITMHA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DAC+ADE | FLAG-Ida | MA | Asp+AraC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are randomized to receive 5 days of single agent decitabine as part of Induction I and then receive Induction II and high-risk Intensifications I &amp; II without decitabine. Patients may receive stem cell transplant depending on donor availability.
Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G-CSF, mitoxantrone, erwinia asparaginase, ITMHA, stem cell transplant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | MA | Asp+AraC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I &amp; II and then receive high-risk Intensifications I &amp; II without decitabine. Patients may receive stem cell transplant depending on donor availability.
Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G-CSF, mitoxantrone, erwinia asparaginase, ITMHA, stem cell transplant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+MA | Asp+AraC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I &amp; II and high-risk Intensifications I &amp; II. Patients may receive stem cell transplant depending on donor availability.
Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G-CSF, mitoxantrone, erwinia asparaginase, ITMHA, stem cell transplant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+MA | DAC+Asp+AraC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I &amp; II and high-risk Intensifications I and then receive low-risk induction II without decitabine. Patients may receive stem cell transplant depending on donor availability.
Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G-CSF, mitoxantrone, erwinia asparaginase, ITMHA, stem cell transplant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DAC+ADE | FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are randomized to receive 5 days of single agent decitabine as part of Induction I and then receive Induction II and high-risk Intensifications I &amp; II without decitabine. Sorafenib is added to the last three courses of chemotherapy. Patients may receive stem cell transplant depending on donor availability.
Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G-CSF, sorafenib, mitoxantrone, erwinia asparaginase, ITMHA, stem cell transplant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I &amp; II and then receive high-risk Intensifications I &amp; II without decitabine. Sorafenib is added to the last three courses of chemotherapy. Patients may receive stem cell transplant depending on donor availability.
Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G-CSF, sorafenib, mitoxantrone, erwinia asparaginase, ITMHA, stem cell transplant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida+Sor | DAC+MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I &amp; II and high-risk Intensifications I &amp; II. Sorafenib is added to the last three courses of chemotherapy. Patients may receive stem cell transplant depending on donor availability.
Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G-CSF, sorafenib, mitoxantrone, erwinia asparaginase, ITMHA, stem cell transplant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida+Sor | DAC+MA+Sor | DAC+Asp+AraC+Sor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are randomized to receive 5 days of single agent decitabine as part of Inductions I &amp; II and high-risk Intensifications I and then receive low-risk induction II without decitabine. Sorafenib is added to the last three courses of chemotherapy. Patients may receive stem cell transplant depending on donor availability.
Interventions: decitabine, cytarabine, daunorubicin, etoposide, dexrazoxane, fludarabine, idarubicin, G-CSF, sorafenib, mitoxantrone, erwinia asparaginase, ITMHA, stem cell transplant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Azacitidine solution is administered intravenously (IV) over a period of 10-40 minutes.</description>
    <arm_group_label>AZA+ADE | FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+AE | AZA+MA</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+AE | MA</arm_group_label>
    <arm_group_label>AZA+ADE | FLAG-Ida |MA | Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | MA | Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+MA | Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+MA | AZA+Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida+Sor | AZA+MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida+Sor | AZA+MA+Sor | AZA+Asp+AraC+Sor</arm_group_label>
    <other_name>Vidaza®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <description>Administered by IV injection over approximately one hour.</description>
    <arm_group_label>DAC+ADE | FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+AE | DAC+MA</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+AE | MA</arm_group_label>
    <arm_group_label>DAC+ADE | FLAG-Ida | MA | Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | MA | Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+MA | Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+MA | DAC+Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida+Sor | DAC+MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida+Sor | DAC+MA+Sor | DAC+Asp+AraC+Sor</arm_group_label>
    <other_name>Dacogen®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given IV or intrathecally (IT).</description>
    <arm_group_label>AZA+ADE | FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+AE | AZA+MA</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+AE | MA</arm_group_label>
    <arm_group_label>AZA+ADE | FLAG-Ida |MA | Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | MA | Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+MA | Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+MA | AZA+Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida+Sor | AZA+MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida+Sor | AZA+MA+Sor | AZA+Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+AE | DAC+MA</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+AE | MA</arm_group_label>
    <arm_group_label>DAC+ADE | FLAG-Ida | MA | Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | MA | Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+MA | Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+MA | DAC+Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida+Sor | DAC+MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida+Sor | DAC+MA+Sor | DAC+Asp+AraC+Sor</arm_group_label>
    <other_name>Ara-C</other_name>
    <other_name>Cytosar®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin</intervention_name>
    <description>Given IV.</description>
    <arm_group_label>AZA+ADE | FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+AE | AZA+MA</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+AE | MA</arm_group_label>
    <arm_group_label>AZA+ADE | FLAG-Ida |MA | Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | MA | Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+MA | Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+MA | AZA+Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida+Sor | AZA+MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida+Sor | AZA+MA+Sor | AZA+Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+AE | DAC+MA</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+AE | MA</arm_group_label>
    <arm_group_label>DAC+ADE | FLAG-Ida | MA | Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | MA | Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+MA | Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+MA | DAC+Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida+Sor | DAC+MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida+Sor | DAC+MA+Sor | DAC+Asp+AraC+Sor</arm_group_label>
    <other_name>Daunomycin</other_name>
    <other_name>Cerubidine®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Given IV.</description>
    <arm_group_label>AZA+ADE | FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+AE | AZA+MA</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+AE | MA</arm_group_label>
    <arm_group_label>AZA+ADE | FLAG-Ida |MA | Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | MA | Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+MA | Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+MA | AZA+Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida+Sor | AZA+MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida+Sor | AZA+MA+Sor | AZA+Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+AE | DAC+MA</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+AE | MA</arm_group_label>
    <arm_group_label>DAC+ADE | FLAG-Ida | MA | Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | MA | Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+MA | Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+MA | DAC+Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida+Sor | DAC+MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida+Sor | DAC+MA+Sor | DAC+Asp+AraC+Sor</arm_group_label>
    <other_name>Vepesid®</other_name>
    <other_name>VP-16</other_name>
    <other_name>Etoposide Phosphate</other_name>
    <other_name>Etopophos®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>ITMHA</intervention_name>
    <description>Given IT.</description>
    <arm_group_label>AZA+ADE | FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+AE | AZA+MA</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+AE | MA</arm_group_label>
    <arm_group_label>AZA+ADE | FLAG-Ida |MA | Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | MA | Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+MA | Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+MA | AZA+Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida+Sor | AZA+MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida+Sor | AZA+MA+Sor | AZA+Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+AE | DAC+MA</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+AE | MA</arm_group_label>
    <arm_group_label>DAC+ADE | FLAG-Ida | MA | Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | MA | Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+MA | Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+MA | DAC+Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida+Sor | DAC+MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida+Sor | DAC+MA+Sor | DAC+Asp+AraC+Sor</arm_group_label>
    <other_name>Intrathecal Triples</other_name>
    <other_name>Methotrexate/Hydrocortisone/Cytarabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idarubicin</intervention_name>
    <description>Given IV.</description>
    <arm_group_label>AZA+ADE | FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+AE | AZA+MA</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+AE | MA</arm_group_label>
    <arm_group_label>AZA+ADE | FLAG-Ida |MA | Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | MA | Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+MA | Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+MA | AZA+Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida+Sor | AZA+MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida+Sor | AZA+MA+Sor | AZA+Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+AE | DAC+MA</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+AE | MA</arm_group_label>
    <arm_group_label>DAC+ADE | FLAG-Ida | MA | Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | MA | Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+MA | Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+MA | DAC+Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida+Sor | DAC+MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida+Sor | DAC+MA+Sor | DAC+Asp+AraC+Sor</arm_group_label>
    <other_name>Idamycin PFS®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given IV over approximately 30 minutes.</description>
    <arm_group_label>AZA+ADE | FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+AE | AZA+MA</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+AE | MA</arm_group_label>
    <arm_group_label>AZA+ADE | FLAG-Ida |MA | Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | MA | Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+MA | Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+MA | AZA+Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida+Sor | AZA+MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida+Sor | AZA+MA+Sor | AZA+Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+AE | DAC+MA</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+AE | MA</arm_group_label>
    <arm_group_label>DAC+ADE | FLAG-Ida | MA | Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | MA | Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+MA | Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+MA | DAC+Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida+Sor | DAC+MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida+Sor | DAC+MA+Sor | DAC+Asp+AraC+Sor</arm_group_label>
    <other_name>Fludara®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitoxantrone</intervention_name>
    <description>Given IV.</description>
    <arm_group_label>AZA+ADE | FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+AE | AZA+MA</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+AE | MA</arm_group_label>
    <arm_group_label>AZA+ADE | FLAG-Ida |MA | Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | MA | Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+MA | Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+MA | AZA+Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida+Sor | AZA+MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida+Sor | AZA+MA+Sor | AZA+Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+AE | DAC+MA</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+AE | MA</arm_group_label>
    <arm_group_label>DAC+ADE | FLAG-Ida | MA | Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | MA | Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+MA | Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+MA | DAC+Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida+Sor | DAC+MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida+Sor | DAC+MA+Sor | DAC+Asp+AraC+Sor</arm_group_label>
    <other_name>Novantrone®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erwinia asparaginase</intervention_name>
    <description>Given IV or intramuscularly (IM).</description>
    <arm_group_label>AZA+ADE | FLAG-Ida |MA | Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | MA | Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+MA | Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+MA | AZA+Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida+Sor | AZA+MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida+Sor | AZA+MA+Sor | AZA+Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | FLAG-Ida | MA | Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | MA | Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+MA | Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+MA | DAC+Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida+Sor | DAC+MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida+Sor | DAC+MA+Sor | DAC+Asp+AraC+Sor</arm_group_label>
    <other_name>Asparaginase Erwinia chrysanthemi</other_name>
    <other_name>Erwinaze®</other_name>
    <other_name>Crisantaspase®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Given PO. Used only for participants with FLT3 ITD and NUP98-NSD1.</description>
    <arm_group_label>AZA+ADE | FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida+Sor | AZA+MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida+Sor | AZA+MA+Sor | AZA+Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida+Sor | DAC+MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida+Sor | DAC+MA+Sor | DAC+Asp+AraC+Sor</arm_group_label>
    <other_name>Nexavar®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>Given IV.</description>
    <arm_group_label>AZA+ADE | FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+AE | AZA+MA</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+AE | MA</arm_group_label>
    <arm_group_label>AZA+ADE | FLAG-Ida |MA | Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | MA | Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+MA | Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+MA | AZA+Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida+Sor | AZA+MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida+Sor | AZA+MA+Sor | AZA+Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+AE | DAC+MA</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+AE | MA</arm_group_label>
    <arm_group_label>DAC+ADE | FLAG-Ida | MA | Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | MA | Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+MA | Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+MA | DAC+Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida+Sor | DAC+MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida+Sor | DAC+MA+Sor | DAC+Asp+AraC+Sor</arm_group_label>
    <other_name>Neupogen</other_name>
    <other_name>Filgrastim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexrazoxane</intervention_name>
    <description>Given IV immediately before idarubicin administration.</description>
    <arm_group_label>AZA+ADE | FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+AE | AZA+MA</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+AE | MA</arm_group_label>
    <arm_group_label>AZA+ADE | FLAG-Ida |MA | Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | MA | Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+MA | Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+MA | AZA+Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida+Sor | AZA+MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida+Sor | AZA+MA+Sor | AZA+Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | AE | MA</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+AE | DAC+MA</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+AE | MA</arm_group_label>
    <arm_group_label>DAC+ADE | FLAG-Ida | MA | Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | MA | Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+MA | Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+MA | DAC+Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida+Sor | DAC+MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida+Sor | DAC+MA+Sor | DAC+Asp+AraC+Sor</arm_group_label>
    <other_name>Zinecard®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Stem Cell Transplant</intervention_name>
    <description>The transplant protocol will depend on the patient's donor and transplant physician's preference.</description>
    <arm_group_label>AZA+ADE | FLAG-Ida |MA | Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | MA | Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+MA | Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida | AZA+MA | AZA+Asp+AraC</arm_group_label>
    <arm_group_label>AZA+ADE | FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida+Sor | AZA+MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>AZA+ADE | AZA+FLAG-Ida+Sor | AZA+MA+Sor | AZA+Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | FLAG-Ida | MA | Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | MA | Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+MA | Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida | DAC+MA | DAC+Asp+AraC</arm_group_label>
    <arm_group_label>DAC+ADE | FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida+Sor | MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida+Sor | DAC+MA+Sor | Asp+AraC+Sor</arm_group_label>
    <arm_group_label>DAC+ADE | DAC+FLAG-Ida+Sor | DAC+MA+Sor | DAC+Asp+AraC+Sor</arm_group_label>
    <other_name>SCT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  Diagnostic criteria: Patients must have one of the following diagnoses:

               -  Acute myeloid leukemia fulfilling the criteria of the WHO Classification (see
                  Appendix I), or

               -  &gt;5% but &lt; 20% marrow myeloblasts and evidence of a clonal de novo AML genetic
                  abnormality [e.g., t(8;21), inv(16), t(9;11)], or

               -  Myeloid sarcoma (also referred to as extramedullary myeloid tumor, granulocytic
                  sarcoma, or chloroma), with or without evidence of a leukemia process in the bone
                  marrow or peripheral blood, with confirmation of myeloid differentiation, or

               -  High grade myelodysplastic syndrome (MDS) with greater than 5% blasts, or

               -  Patients with treatment related myeloid neoplasms including AML and MDS, provided
                  their cumulative anthracycline dose has not exceeded 230 mg/m2 doxorubicin
                  equivalents.

          -  Other criteria - Patients must meet all the following criteria:

               -  Age &gt; 28 days and &lt; 22 years at time of study entry inclusive, and

               -  No prior therapy for this malignancy except for one dose of intrathecal therapy
                  and the use of hydroxyurea or low-dose cytarabine (100-200 mg/m2 per day for one
                  week or less for hyperleukocytosis), and

               -  Written informed consent according to institutional guidelines, and

               -  Female patients of childbearing potential must have a negative pregnancy test
                  within 2 weeks prior to enrollment, and

               -  Male and female participants of reproductive potential must use an effective
                  contraceptive method during the study and for a minimum of 6 months after study
                  treatment.

        EXCLUSION CRITERIA:

          -  Down syndrome

          -  Acute promyelocytic leukemia (APL)

          -  BCR-ABL1 chronic myeloid leukemia in blast crisis (CML-BC)

          -  Juvenile myelomonocytic leukemia (JMML)

          -  Fanconi anemia (FA)

          -  Kostmann syndrome

          -  Shwachman syndrome

          -  Other bone marrow failure syndromes or low grade (&lt;5% bone marrow blasts) MDS.

          -  Use of concomitant chemotherapy, radiation therapy, or immunotherapy other than as
             specified in the protocol.

          -  Use of investigational agents within 30 days or any anticancer therapy for this
             malignancy within 2 weeks before study entry with the exception of IT therapy,
             hydroxyurea, or low-dose cytarabine as specified in the protocol document. The patient
             must have recovered from all acute toxicities from any previous therapy.

          -  Systemic fungal, bacterial, viral, or other infection not controlled (defined as
             exhibiting ongoing signs/symptoms related to the infection and without improvement,
             despite appropriate antibiotics or other treatment).

          -  Pregnant or lactating.

          -  Any significant concurrent disease, illness, or psychiatric disorder that would
             compromise patient safety or compliance, interfere with consent, study participation,
             follow up, or interpretation of study results.

          -  Prior chemotherapy, with the exception of hydroxyurea or low-dose cytarabine as
             specified in the protocol document. The patient must have recovered from all acute
             toxicities from any previous therapy.

          -  Patients with treatment related myeloid neoplasms with cumulative anthracyclines
             greater than 255 mg/m2 doxorubicin equivalents.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanja A. Gruber, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Jude Children's Research Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tanja A. Gruber, MD, PhD</last_name>
    <phone>866-278-5833</phone>
    <email>tanja.gruber@stjude.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Referral Office</last_name>
    <phone>866-278-5833</phone>
    <email>referralinfo@stjude.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weili Sun, MD,PhD</last_name>
      <phone>800-826-4673</phone>
      <email>weilisun@coh.org</email>
    </contact>
    <investigator>
      <last_name>Weili Sun, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Central California</name>
      <address>
        <city>Madera</city>
        <state>California</state>
        <zip>93636</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faisal Razzaqi, MD</last_name>
      <phone>866-353-5437</phone>
      <email>frazzaqi@valleychildrens.org</email>
    </contact>
    <investigator>
      <last_name>Faisal Razzaqi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norman J. Lacayo, MD</last_name>
      <phone>650-497-8953</phone>
      <email>lacayon@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Norman J. Lacayo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital and Health Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Schiff, MD</last_name>
      <phone>858-966-5983</phone>
      <email>dschiff@chsd.org</email>
    </contact>
    <investigator>
      <last_name>Deborah Schiff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanja A. Gruber, MD, PhD</last_name>
      <phone>866-278-5833</phone>
      <email>tanja.gruber@stjude.org</email>
    </contact>
    <contact_backup>
      <last_name>Referral Office</last_name>
      <phone>866-278-5833</phone>
      <email>referralinfo@stjude.org</email>
    </contact_backup>
    <investigator>
      <last_name>Tanja A. Gruber, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth M. Heym, MD</last_name>
      <phone>682-885-4007</phone>
      <email>kenneth.heym@cookchildrens.org</email>
    </contact>
    <investigator>
      <last_name>Kenneth M. Heym, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stjude.org</url>
    <description>St. Jude Children's Research Hospital</description>
  </link>
  <link>
    <url>http://www.stjude.org/protocols</url>
    <description>Clinical Trials Open at St. Jude</description>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2017</study_first_submitted>
  <study_first_submitted_qc>May 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2017</study_first_posted>
  <last_update_submitted>December 19, 2017</last_update_submitted>
  <last_update_submitted_qc>December 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DNA methyltransferase inhibitors</keyword>
  <keyword>Acute myeloid leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>Dexrazoxane</mesh_term>
    <mesh_term>Razoxane</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

